Non-Invasive Ventilation In Patients With Acute Pulmonary Edema
Abstract:
Acute pulmonary edema (APE) is a life-threatening condition with a high mortality rate. It has two types: cardiogenic, which usually happens when a previously asymptomatic condition decompensates, and non cardiogenic, which is brought on by other factors. Hypoxemia and decreased pulmonary compliance are the results of both types of ventilation impairment. In order to reduce venous return, lower left ventricular afterload, and relieve pulmonary edema, management involves medication and noninvasive ventilation (NIV). As a result, vital signs improve, and the chance of needing intubation decreases. BiPAP and CPAP, primarily used in cardiogenic APE, enhance hemodynamics, oxygenation, and breathing effort. They are more successful in symptom relief than oxygen therapy alone, but no conclusive evidence exists that they lower short-term mortality. Both cardiogenic and non-cardiogenic APE patients can benefit from NIV since it lowers respiratory effort and dyspnea without requiring endotracheal intubation. By increasing intrathoracic pressure through positive pressure, NIV improves pulmonary compliance and reduces respiratory effort. Studies indicate that Noninvasive Pressure Support Ventilation (NIPSV) and Continuous Positive Airway Pressure (CPAP) are equally effective in reducing mortality and intubation rates. However, NIPSV is associated with faster resolution of respiratory failure, though it does not significantly improve final clinical outcomes over CPAP. Thus, while both modalities are effective, NIPSV may be preferred for quicker recovery. In order to maximize oxygenation, lessen respiratory effort, and enhance cardiac function, initiating NIV in APE necessitates precise ventilator settings and vigilant monitoring. Despite its benefits, NIV is contraindicated in cases of airway protection failure, severe hemodynamic instability, facial trauma, severe gastrointestinal issues, massive hemoptysis, excessive secretions, cardiac arrest, and upper airway obstruction. NIV remains a first-line treatment for APE due to its effectiveness and safety profile. It is a well-tolerated intervention with adverse event rates comparable to drug therapy alone, making it a key component in the management of acute pulmonary edema.
